Cargando…

The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies

Extracellular matrix metalloproteinase inducer (EMMPRIN) has been reported to be associated with tumor formation and invasion in many studies. However, the clinicopathological significance and prognosis of EMMPRIN in cancer patients remains inconclusive. Therefore, we conducted a meta-analysis to as...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Hengwei, Yi, Wanwan, Wang, Chenxing, Wang, Jisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669917/
https://www.ncbi.nlm.nih.gov/pubmed/29137291
http://dx.doi.org/10.18632/oncotarget.19740
_version_ 1783275929397624832
author Fan, Hengwei
Yi, Wanwan
Wang, Chenxing
Wang, Jisheng
author_facet Fan, Hengwei
Yi, Wanwan
Wang, Chenxing
Wang, Jisheng
author_sort Fan, Hengwei
collection PubMed
description Extracellular matrix metalloproteinase inducer (EMMPRIN) has been reported to be associated with tumor formation and invasion in many studies. However, the clinicopathological significance and prognosis of EMMPRIN in cancer patients remains inconclusive. Therefore, we conducted a meta-analysis to assess the predictive potential of EMMPRIN in various cancers. By searching Pubmed, Cochrane library database and web of science comprehensively, 39studies with 5739 cases were included in our meta-analysis. The results indicated that EMMPRIN overexpression was significantly associated with poor outcome of cancers (HR=2.46, 95% CI: 2.21-2.75, P<0.0001). In addition, a significant relation was found between EMMPRIN overexpression and clinicopathological features, such as tumor stage (T3+T4/ T1+T2, OR=1.87, 95% CI:1.64-2.12, P<0.0001), tumor differentiation (poor/ well+ moderate, OR=1.09, 95% CI:1.60-2.23, P<0.0001), clinical stage (III+IV /I +II, OR=1.96, 95% CI:1.69-2.27, P<0.0001) and nodal metastasis (positive/negative, OR=2.37, 95% CI:1.93-2.90, P<0.0001). However, the expression of EMMRIN was not significantly associated with tumor stage in cervical cancer (OR=1.35, 95%CI: 0.73-2.48, P=0.33). In conclusion, EMMPRIN overxepression is significantly associated with clinicopathological characteristics and prognosis of cancers. Thus, EMMPRIN may be regarded as a promising bio-marker in predicting the clinical outcome of patients in cancers and could be used as the therapeutic target during clinical practices.
format Online
Article
Text
id pubmed-5669917
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56699172017-11-09 The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies Fan, Hengwei Yi, Wanwan Wang, Chenxing Wang, Jisheng Oncotarget Research Paper Extracellular matrix metalloproteinase inducer (EMMPRIN) has been reported to be associated with tumor formation and invasion in many studies. However, the clinicopathological significance and prognosis of EMMPRIN in cancer patients remains inconclusive. Therefore, we conducted a meta-analysis to assess the predictive potential of EMMPRIN in various cancers. By searching Pubmed, Cochrane library database and web of science comprehensively, 39studies with 5739 cases were included in our meta-analysis. The results indicated that EMMPRIN overexpression was significantly associated with poor outcome of cancers (HR=2.46, 95% CI: 2.21-2.75, P<0.0001). In addition, a significant relation was found between EMMPRIN overexpression and clinicopathological features, such as tumor stage (T3+T4/ T1+T2, OR=1.87, 95% CI:1.64-2.12, P<0.0001), tumor differentiation (poor/ well+ moderate, OR=1.09, 95% CI:1.60-2.23, P<0.0001), clinical stage (III+IV /I +II, OR=1.96, 95% CI:1.69-2.27, P<0.0001) and nodal metastasis (positive/negative, OR=2.37, 95% CI:1.93-2.90, P<0.0001). However, the expression of EMMRIN was not significantly associated with tumor stage in cervical cancer (OR=1.35, 95%CI: 0.73-2.48, P=0.33). In conclusion, EMMPRIN overxepression is significantly associated with clinicopathological characteristics and prognosis of cancers. Thus, EMMPRIN may be regarded as a promising bio-marker in predicting the clinical outcome of patients in cancers and could be used as the therapeutic target during clinical practices. Impact Journals LLC 2017-07-31 /pmc/articles/PMC5669917/ /pubmed/29137291 http://dx.doi.org/10.18632/oncotarget.19740 Text en Copyright: © 2017 Fan et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Fan, Hengwei
Yi, Wanwan
Wang, Chenxing
Wang, Jisheng
The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies
title The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies
title_full The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies
title_fullStr The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies
title_full_unstemmed The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies
title_short The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies
title_sort clinicopathological significance and prognostic value of emmprin overexpression in cancers: evidence from 39 cohort studies
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669917/
https://www.ncbi.nlm.nih.gov/pubmed/29137291
http://dx.doi.org/10.18632/oncotarget.19740
work_keys_str_mv AT fanhengwei theclinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies
AT yiwanwan theclinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies
AT wangchenxing theclinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies
AT wangjisheng theclinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies
AT fanhengwei clinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies
AT yiwanwan clinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies
AT wangchenxing clinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies
AT wangjisheng clinicopathologicalsignificanceandprognosticvalueofemmprinoverexpressionincancersevidencefrom39cohortstudies